Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 69 out of 100. Clinical trials

Topic: Brain proteins, microglia and lab models

Plain-language summary

The primary outcome was difference in the change in Neuropsychiatric Inventory apathy scores for oxytocin versus placebo periods in the per-protocol population after 6 weeks of treatment. Interpretation Intranasal oxytocin given every third day was well tolerated and was associated with a small reduction in apathy in patients with frontotemporal dementia.

What this study adds

Evidence grade: Early

The record lists 94 participants. In this phase 2 trial, intranasal oxytocin given every third day was well tolerated and was associated with a small reduction in apathy in people with frontotemporal dementia. Reported effect size: NPI apathy change -1.32 points (95% CI -2.43 to -0.21) vs placebo.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Coleman, K. K. L., Berry, S., Cummings, J., Hsiung, G. R., Laforce, R., Huey, E., et al. (2025). Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial. The Lancet Neurology. https://doi.org/10.1016/S1474-4422(24)00456-3

Vancouver

Coleman KKL, Berry S, Cummings J, Hsiung GR, Laforce R, Huey E, et al. Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial. The Lancet Neurology. 2025. doi:10.1016/S1474-4422(24)00456-3. PMID: 39862881.

BibTeX

@article{coleman2025-39862881,
  author  = {Coleman, K. K. L. and Berry, S. and Cummings, J. and Hsiung, G. R. and Laforce, R. and Huey, E. and Ducharme, S. and Tartaglia, M. C. and Mendez, M. F. and Onyike, C. and others},
  title   = {{Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial}},
  journal = {The Lancet Neurology},
  year    = {2025},
  doi     = {10.1016/S1474-4422(24)00456-3},
  pmid    = {39862881},
  url     = {https://doi.org/10.1016/S1474-4422(24)00456-3}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In this phase 2 trial, intranasal oxytocin given every third day was well tolerated and was associated with a small reduction in apathy in people with frontotemporal dementia. The findings are from a per-protocol analysis.

Study details

Limitations

Small effect on an informant-rated scale; crossover design with washout; only 82% completed both periods in stage 2; per-protocol primary analysis.

How this study scored 69/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 3 of 4; Study design 8 of 12; Strength of evidence 2 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 1 of 4; Effect reported 3 of 3; Studied in people 3 of 3; Randomized / blinded 2 of 2; Times cited 3 of 7; Citations per year 2 of 5; Impact for its field and year 4 of 6; Cited by studies here 1 of 6; Still being cited 2 of 4; Senior author's track record 3 of 4; Institution's track record 3 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read left out, no data. 68 of the 98 points it could be judged on, which is 69 of 100. Total 69 of 100.68 of the 98 points we could judge = 69 of 100

Published in a leading specialty journal, and it is a mid-stage phase 2 trial. We have no data on free to read, so that was left out: it earned 68 of the 98 points we could judge it on, which is 69 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (The Lancet Neurology)
Journal's citation record 3 / 4 The Lancet Neurology: journal h-index 457 (OpenAlex, 2026-10-29)
Study design 8 / 12 A mid-stage phase 2 trial
Strength of evidence 2 / 5 Rated “early” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 1 / 4 94 participants
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 2 / 2 Randomized and blinded or placebo-controlled (as stated in the record)
Times cited 3 / 7 Cited 18 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 6.0 citations a year over 3 year(s) since 2025
Impact for its field and year 4 / 6 Cited 11.4× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 2 other studies in this library
Still being cited 2 / 4 Cited 18 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Elizabeth C. Finger: h-index 81 (OpenAlex, whole career)
Institution's track record 3 / 3 University of Washington: institution h-index 3,540 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 24 institution(s) in 3 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 39862881)
Free to read — / 2 Access not recorded — left out of this score
Points 68 / 98 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 68 of the 98 points we could judge it on is 69 out of 100.
Total 69 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

2 studies in the alzhub library list this one in their references.

Related studies in Clinical trials from nearby years

Also tagged “tdp-43”

1,150 studies in the library carry the topic tag “tdp-43”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Clinical trials

See all studies in Clinical trials →